MacroGenics, Inc. (MGNX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-13) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-09) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-14) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-20) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-05) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-09) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-07) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-06) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-09) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Commitments and Contingencies | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Employee Benefit Plan | — |
|
| Fair Value of Financial Instruments | — |
|
| In-licensing Arrangement | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Inventory | — |
|
| Inventory, Net | — |
|
| Marketable Securities | ||
| Nature of Operations | — |
|
| Net Income (loss) Per Share | — |
|
| Net Loss Per Share | — |
|
| Organization and Nature of Operations | — |
|
| Pay Vs Performance Disclosure | ||
| Property, Equipment and Software | — |
|
| Revenue | ||
| Royalty Monetization Agreement | — |
|
| Royalty Monetization Arrangement | ||
| Segment Reporting | ||
| Stock-based Compensation | ||
| Stockholders' Equity | ||
| Subsequent Event | — |
|
| Summary of Significant Accounting Policies | ||
| Tesera Transaction | — |
|